Ascendis plans a once-monthly obesity drug after its Novo deal ends
- Posted on September 14, 2026
- By Google News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Ascendis plans a once-monthly obesity drug after its Novo deal ends
Ascendis plans multiple metabolic and cardiovascular programs, including TransCon Semaglutide for obesity and type 2 diabetes, with no continuing financial obligations.